VENLO, The Netherlands, February 8/PRNewswire-FirstCall/ -- QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that its wholly owned subsidiary DxS has acquired the global and exclusive licence for biomarker PI3K from Johns Hopkins University to develop real-time-PCR and endpoint PCR assays. [more]
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 8, 2010 - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has awarded a Notice of Allowance for the “Soutschek and Manoharan” patent (Application No. 10/916,185), which covers certain chemically modified siRNAs of any length directed to any target, including siRNAs with sterol conjugates for in vivo delivery. [more]
SAN DIEGO, Calif., Feb. 8 /PRNewswire/ -- NexBio, Inc. today announced the issuance by the United States Patent and Trademark Office of United States Patent No. 7,645,448 entitled "Class of Therapeutic Protein Based Molecules". This patent covers NexBio's sialidase pharmaceutical compositions, including its lead compound DAS181 (Fludase®), and methods of treating or preventing viral infection by influenza and parainfluenza with such compositions. [more]
London and Palo Alto, CA, February 8, 2010 – Silence Therapeutics plc (AIM: SLN) today announced that the United States Patent and Trademark Office (USPTO) has issued the company a notice of allowance on a patent application directed to methods of treatment using a high-value therapeutic target in the area of oncology. [more]
LONDON and PALO ALTO, Calif., Feb. 8 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) today announced that the United States Patent and Trademark Office (USPTO) has issued the company a notice of allowance on a patent application directed to methods of treatment using a high-value therapeutic target in the area of oncology [more]
SAN DIEGO, Feb. 4 /PRNewswire/ -- Fate Therapeutics, Inc. received a Notice of Allowance from the United States Patent and Trademark Office for U.S. Patent Application Number 10/997,146 entitled "Methods for Reprogramming Somatic Cells." Upon issuance, the patent will cover foundational induced pluripotent stem cell (iPSC) technology for identifying agents that enable the reprogramming of human somatic cells, including pluripotency genes, small molecules and biologics. [more]
WALTHAM, Mass., Feb. 3 /PRNewswire-FirstCall/ -- Repligen Corporation (NASDAQ:RGEN) announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office for a patent covering a recombinant form of Protein A which is identical in structure to the commercial form of Protein A from Staphylococcus aureus which is used in the production of many of the world's approved monoclonal antibodies. [more]
REHOVOT, Israel & PHILADELPHIA--(BUSINESS WIRE)--Feb 3, 2010 - Rosetta Genomics (NASDAQ:ROSG) today announced that the United States Patent and Trademark Office (USPTO) has issued three patents to the company covering the composition of matter of human microRNAs. [more]
WALTHAM, MA – February 3, 2010 – Repligen Corporation (NASDAQ: RGEN) announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office for a patent covering a recombinant form of Protein A which is identical in structure to the commercial form of Protein A from Staphylococcus aureus which is used in the production of many of the world’s approved monoclonal antibodies. [more]
Ann Arbor, Mich. (February 2, 2010) – NanoBio Corporation announced today that a sixth U.S. patent covering its novel nanoemulsion technology has been awarded. The patent encompasses composition of matter claims for the company’s lead anti-infective and vaccine product candidates. [more]
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb 2, 2010 - Fluxion Biosciences, Inc. announced today that a lawsuit alleging patent infringement had been filed against it in the US District Court of Northern California by Cellectricon AB, its competitor in the field of automated ion channel screening systems for drug discovery. [more]
EWING, N.J.--(BUSINESS WIRE)--Feb 2, 2010 - Antares Pharma, Inc. (NYSE Amex: AIS) a leader in self injection drug delivery technology today announced that Teva USA has introduced new patient support resources for the Tjet® device and TEV-TROPIN [somatropin (rDNA origin) for injection]. [more]
ANN ARBOR, Mich.--(BUSINESS WIRE)--Feb 2, 2010 - NanoBio Corporation announced today that a sixth U.S. patent covering its novel nanoemulsion technology has been awarded. The patent encompasses composition of matter claims for the company's lead anti-infective and vaccine product candidates. [more]
2 February 2010, Adelaide: LBT Innovations Limited (formerly LabTech Systems) (ASX: LBT) the Australian clinical and diagnostic technology developer, has been advised that the European Patent Office has granted its patent for the agar plate streaking technology which is at the core of the company’s MicroStreak system. [more]
Paris, February 2, 2010 - Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application "Glycosylated IL-7, Preparation and Uses", US Patent Application Number 11/996,176. The Notice of Allowance is the USPTO's official communication that the Company's application has successfully completed examination and that a patent will be issued. [more]
NATICK, Mass., Feb. 1 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today announced the settlement of three patent disputes with Johnson & Johnson (J&J). [more]
BRIDGEWATER, N.J., Feb. 1 /PRNewswire/ -- Cordis Corporation, a Johnson & Johnson company, announced today that it has reached an agreement with Boston Scientific resolving two Delaware litigations related to Cordis's Palmaz and Gray patents and Boston Scientific's Jang patents. [more]
GOTHENBURG, Sweden, February 1/PRNewswire/ -- Cellectricon AB today announced that it has resumed its litigation against Fluxion Biosciences, Inc. Cellectricon filed the lawsuit in July 2009 in the United States District Court for the Northern District of California alleging infringement of several United States patents issued or licensed to Cellectricon for microfluidic technology used in Cellectricon's state-of-the-art ion channel drug screening solution, the Dynaflow HT System. [more]
FRANKLIN, Tenn.--(BUSINESS WIRE)--Feb 1, 2010 - BioMimetic Therapeutics, Inc. announced today the European Patent Office (EPO) intends to grant patent application No. 05803356 titled “Platelet-Derived Growth Factor Compositions and Methods of Use Thereof”. [more]
MENLO PARK, Calif., Feb 01, 2010 (BUSINESS WIRE) -- Depomed, Inc. announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a U.S. patent application (No. 12/239,591) directed to pharmaceutical dosage forms that deliver the compound gabapentin via Depomed's proprietary Acuform gastric retentive drug delivery technology. [more]
Mergers & Acquisitions, Partnerships, & Collaborations 2010 – Review and Outlook
This PharmaLive Special Report analyzes the healthcare industry’s M&As of 2009, providing a comprehensive listing of companies’ M&A activity and detailing the top 20 deals within each of the Pharmaceutical, Biotechnology, Specialty, and Medical Device sectors, and previews potential M&A activity within the healthcare arena for 2010.
The introductory rate of $395 expires February 17, 2010.
